In the light of the lack of approved pharmacological strategies for NAFLD and limited therapeutic options for NAFLD-related HCC, the results obtained in the present study suggest that the novel liver THRβ agonist TG68 might represent an attractive candidate for the treatment of NAFLD and NAFLD-related HCC (Figure 7). The gene discussed is THRB; the disease is metabolic dysfunction-associated steatotic liver disease.